Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus.
about
Automated Triplex (HBV, HCV and HIV) NAT Assay Systems for Blood Screening in IndiaCurrent methods for the reduction of blood-borne pathogens: a comprehensive literature reviewA Novel Diagnostic Target in the Hepatitis C Virus GenomePathogen inactivation technologies for cellular blood components: an updatePooling nasopharyngeal/throat swab specimens to increase testing capacity for influenza viruses by PCR.Transfusion of Packed Red Cells: Indications, Triggers and Adverse Events.Low compliance of men having sex with men with self-deferral from blood donation in a Chinese populationSavoring every drop - vampire or mosquito?Transfusion-transmitted human immunodeficiency virus (HIV) from seroconverting donors is rare in England and Wales: results from HIV lookback, October 1995 through December 2008.Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?Sufficient blood, safe blood: can we have both?Pooled nucleic acid testing to detect antiretroviral treatment failure in Mexico.Prevalence of occult hepatitis B virus infectionManagement of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma.Two-stage hierarchical group testing for multiple infections with application to the infertility prevention project.Cost-effective pooling of DNA from nasopharyngeal swab samples for large-scale detection of bacteria by real-time PCR.The present and future of Transfusion MedicineCriteria for hepatitis B virus screening and validation of blood components in Italy: the position of the SIMTI HBV working group.Reducing the risk of hepatitis B virus transfusion-transmitted infectionKnowledge of HIV testing and attitudes towards blood donation at three blood centres in Brazil.Perioperative Red Blood Cell Transfusion: Harmful or Beneficial to the Patient?Individual donor-nucleic acid testing for human immunodeficiency virus-1, hepatitis C virus and hepatitis B virus and its role in blood safetyUndisclosed human immunodeficiency virus risk factors identified through a computer-based questionnaire program among blood donors in Brazil.Implementation of an HIV-1 Triple-Target NAT Assay in the Routine Screening at Three German Red Cross Blood Centres.Human Immunodeficiency Virus (HIV).Factors in enhancing blood safety by nucleic acid technology testing for human immunodeficiency virus, hepatitis C virus and hepatitis B virus.Emerging Pathogens - How Safe is Blood?Estimating the prevalence of multiple diseases from two-stage hierarchical pooling.Molecular HIV screening.Historical epidemiology of hepatitis C virus (HCV) in selected countries.First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany.Implementation of Bacterial Detection Methods into Blood Donor Screening - Overview of Different Technologies.Cost effectiveness of adding nucleic acid testing to hepatitis B, hepatitis C, and human immunodeficiency virus screening of blood donations in Zimbabwe.[Human immunodeficiency virus: position of Blood Working Group of the Federal Ministry of Health].Evaluation of the effectiveness of a pathogen inactivation technology against clinically relevant transfusion-transmitted bacterial strains.Head-to-head comparison between two screening systems for HBsAG, anti-HBc, anti-HCV and HIV combination immunoassays in an international, multicentre evaluation study.Estimating the residual risk for HIV, HCV and HBV in different types of platelet concentrates in Germany.Virus NAT for HIV, HBV, and HCV in Post-Mortal Blood Specimens over 48 h after Death of Infected Patients - First Results.Nucleic acid testing-benefits and constraints.Whole blood pathogen reduction technology and blood safety in sub-Saharan Africa: A systematic review with regional discussion.
P2860
Q26752681-2DBA2809-FB53-462F-B075-3817B1EB8743Q26996247-6491B244-41E9-473D-AEE1-8807ABC54AE7Q27487878-143C6445-4318-44A8-9CA6-0FA2F5DB3FE5Q28655769-C6706609-F84C-4D81-B138-B1E91CDBF8D5Q30411137-64FD0401-4EF0-4589-8592-B94409C3934BQ33424970-FB48ED1C-BFDD-4F8C-B57D-203E5C776DD9Q33690833-CC16DADF-9E78-41E1-B9F5-175EA252A13CQ33752207-215C3DF0-4F18-4B28-B1CC-CF9855589E52Q33777205-1A8CF2AC-399D-4829-A2EE-F44B639C6B48Q33841435-C582860F-8C03-4126-9CF6-52C2B0172E92Q34206713-4E7FC072-0258-4079-8B8D-E94F1E5ACBFBQ34574727-C7649F4C-FFBA-485D-B53C-FEA15F004C7EQ34757367-754B793B-F63E-4B09-962A-64C81AAA2FE1Q35095916-790E6E24-071F-4C68-9A5F-7F92AE8F74B6Q35212358-5EE0E0DA-401F-4A2E-A6D6-F32E258EA5B4Q35331173-C2A4A5BA-A80F-4990-8705-AED7D39A20E1Q35434303-3638E495-C747-4561-9918-6B2D526AEBE1Q35434455-FCCF3C5D-A760-4B36-89DB-411D38459AAFQ35683881-1935BD80-B681-4050-8E13-9362734B1904Q35683972-FB24BEF9-4E96-4FF9-8575-422DD6C4073EQ35998347-82A39615-06BA-4472-B706-A5967BD657F5Q36034896-546AAFD2-D01E-4902-84BD-972CFBC23B74Q37004488-B2640A16-EF43-4CA6-9004-53D7D95A2526Q37045800-97EA8D02-CB53-40E7-923C-19E7CD2B05F0Q37045832-83319140-E165-49E9-ABEA-725731ABE6CEQ37618604-313ACD1D-D306-4FE0-A7EF-C70A9E24115EQ37630317-606F8235-4451-4CCC-901A-0EE2DA952C2DQ37836714-4BEBECEA-64B0-405B-8E17-63EC66C8D2B5Q38142249-A3CA3E57-2AEB-43A9-A248-EF46E8962CBDQ38203033-460928F6-3473-4429-B27F-32E8957DC2A2Q38421534-4E80D8AE-42BE-4BA8-8193-409C2160D173Q38667376-871CC1E1-02E3-40A6-9306-2C2DA4D2E3E6Q40519030-66F2DFC5-40E2-472C-B7EF-D52851938C7AQ40942917-6E7C5179-4695-43FA-B982-1355D6292CBBQ41201448-CC7D5E82-342A-439C-8F19-A271D7D90B2AQ41300211-CF761527-CC0E-4595-BF6C-B23AB1C27A32Q41692988-A03AD3BB-FF0E-4033-8D31-0B2470C527D1Q41878730-F7F59527-F124-40EE-BBDE-3FDA5D58B842Q42000342-3D784573-4C90-46A7-9B62-817E58C424D8Q42015397-ACDA2243-969A-4412-97DD-C4ADE9FDCAFF
P2860
Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Experience of German Red Cross ...... virus, and hepatitis B virus.
@en
Experience of German Red Cross ...... virus, and hepatitis B virus.
@nl
type
label
Experience of German Red Cross ...... virus, and hepatitis B virus.
@en
Experience of German Red Cross ...... virus, and hepatitis B virus.
@nl
prefLabel
Experience of German Red Cross ...... virus, and hepatitis B virus.
@en
Experience of German Red Cross ...... virus, and hepatitis B virus.
@nl
P2093
P1433
P1476
Experience of German Red Cross ...... virus, and hepatitis B virus.
@en
P2093
Christina Mahnhardt
Christine Jork
David J Wright
Erhard Seifried
Geert Geusendam
German Red Cross NAT Study Group
Knut Gubbe
Lutz Pichl
Marijke Weber-Schehl
Michael K Hourfar
P304
P356
10.1111/J.1537-2995.2008.01718.X
P577
2008-05-06T00:00:00Z